Thymosin Alpha-1
Purrptide digest
Thymosin Alpha-1 has been approved in 35 countries for viral hepatitis and cancer immune support. The FDA just never got around to it. Your immune system kept aging regardless. It calibrates T-cells — your immune system's precision soldiers — to be better at recognizing real threats and less likely to misfire on friendly tissue. Less friendly fire, sharper targeting. During COVID, several countries deployed it clinically with promising results. Longevity clinics have been prescribing it off-label for years. The West is slowly reading the memo everyone else got a decade ago.
What this means for you
If immune optimization is your goal, this has more real-world clinical validation than almost anything on this list. Thirty-five country approvals is not nothing.
Legitimate clinical data in viral hepatitis and cancer adjuvant settings. The off-label immune optimization use case is the interesting expansion.
T-cell modulation and thymic output effects are well-characterized. Long-term autoimmune risk with chronic use is underexplored.
Approved in 35 countries, no US/EU approval. That's a regulatory arbitrage opportunity sitting in plain sight for whoever runs the trial.
For the nerds
Thymosin alpha 1: a pleiotropic peptide with therapeutic applications in infectious diseases
Drug Design, Development and Therapy · DOI: 10.2147/DDDT.S172084
Read full paper on PubMed →